NEW YORK (GenomeWeb) – T2 Biosystems reported after the close of the market on Tuesday a 10 percent increase in third quarter revenues, as a sharp increase in product revenues were mostly offset by a decline in research revenues.

Separately, the company announced that it has partnered with Allergan to develop a novel diagnostic panel for the detection of Gram-negative bacterial species and antibiotic resistance in patients with severe bacterial infections.